US10294228B2 – May 21, 2019 – Breathing control modulating compounds, and methods of making and using same

Please complete the required fields.




Inventors :

Scott L. Dax; James Joseph Mencel; Vita Ozola; Edgars Suna; Kirill Shubin

Owner :

GALLEON, LLC, PENNSYLVANIA NEURAD LTD., ISRAEL

Application Number :

US15737431

Document Number :

US10294228B2

Priority Date :

June 23, 2016

Filing Date :

June 23, 2016

Date of Grant/ Publication :

May 21, 2019

Class :

; C07D487 / 04; A61K9 / 00; A61P11 / 00; A61K45 / 06; A61K31 / 485; A61K31 / 519

Abstract

The present invention includes compounds that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound and/or composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound and/or composition of the invention.

Claim(s)

1. A compound that is 1-(2,6-Bis-methylamino-8-propylamino-pyrimido[5,4-d]pyrimidin-4-yl amino)-2-methyl-propan-2-ol (31) or at least one crystalline salt selected from the group consisting of: (xiii) Crystalline hydrochloride salt (31a), with a XRPD spectrum as per FIG. 3A ; XRPD peaks as per FIG. 3B ; and/or DSC spectrum as per FIG. 3C ; (xiv) Crystalline bis-hydrochloride salt (31b), with a XRPD spectrum as per FIG. 4A ; XRPD peaks as per FIG. 4B ; and/or DSC spectrum as per FIG. 4C ; (xv) Crystalline hydrogen malonate salt (31c), with a XRPD spectrum as per FIG. 5A ; XRPD peaks as per FIG. 5B ; and/or DSC spectrum as per FIG. 5C ; (xvi) Crystalline hydrogen maleinate salt Form Male-A (31d-1), with a XRPD spectrum as per FIG. 6A ; XRPD peaks as per FIG. 6B ; and/or DSC spectrum as per FIG. 6C ; (xvii) Crystalline hydrogen maleinate salt Form Male-B (31d-2), with a XRPD spectrum as per FIG. 7A ; XRPD peaks as per FIG. 7B ; and/or DSC spectrum as per FIG. 7C ; (xviii) Crystalline hydrogen fumarate salt (31e), with a XRPD spectrum as per FIG. 8A ; XRPD peaks as per FIG. 8B ; and/or DSC spectrum as per FIG. 8C ; (xix) Crystalline hydrogen L(+)tartrate salt (31f), with a XRPD spectrum as per FIG. 9A ; XRPD peaks as per FIG. 9B ; DSC spectrum as per FIG. 9C ; (xx) Crystalline D,L-mandelate salt (31g), with a XRPD spectrum as per FIG. 10A ; XRPD peaks as per FIG. 10B ; and/or DSC spectrum as per FIG. 10C ; (xxi) Crystalline tosylate salt form Tos-A (31h-1), with a XRPD spectrum as per FIG. 11A ; XRPD peaks as per FIG. 11B ; and/or DSC spectrum as per FIG. 11C ; (xxii) Crystalline tosylate salt form Tos-B (31h-2), with a XRPD spectrum as per FIG. 12A ; XRPD peaks as per FIG. 12B ; and/or DSC spectrum as per FIG. 12C ; (xxiii) Crystalline mesylate salt (31i), with a XRPD spectrum as per FIG. 13A ; XRPD peaks as per FIG. 13B ; and/or DSC spectrum as per FIG. 13C ; (xxiv) Crystalline saccharinate salt (31j), with a XRPD spectrum as per FIG. 14A ; XRPD peaks as per FIG. 14B ; and/or DSC spectrum as per FIG. 14C ; and any mixtures thereof.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login